


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. University Healthcare-Berkeley Medical Center</p> <p>2. 2500 Hospital Drive Martinsburg, WV 25401</p>	<p>In accordance with letter dated March 08, 2024.</p>	<p>4. Expiration Date: October 31, 2025</p>
	<p>3. License No.: 47-15501-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-09218 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-15501-01

Docket or Reference No.:
030-09218

Amendment No. 37

- | | | | |
|--|---|---|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> | <p>7. Chemical and/or physical form</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> | <p>9. Authorized use</p> |
| <p>C. Iodine-125 permitted by 10 CFR 35.400</p> | <p>C. Sealed Sources (Amersham Health/Medi-Physics, Inc., Model 6702; Bard Brachytherapy, Inc., Model STM 125I; BEBIG Isotopentechnik und Umweltdiagnostik, Model I25.S06; Best Medical International, Inc., Model 2301; Core Oncology, Inc. (formerly Mills Biopharmaceuticals, LLC, Model I-125 SL; IsoAid, LLC, Model IAI-125A; Medi-Physics, Inc. D/B/A GE Healthcare, Model 6711; Medi-Physics, Inc. or Amersham Health, Model 6733; North American Scientific, Inc., Model MED3631)</p> | <p>C. 2.5 curies total</p> | <p>C. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</p> |
| <p>D. Any byproduct material permitted by 10 CFR 35.500</p> | <p>D. Sealed Sources (Eckert & Ziegler Isotope Products dba Isotope Products Laboratories, Model PHI-0094)</p> | <p>D. 10 millicuries per source and 40 millicuries total</p> | <p>D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).</p> |
| <p>E. Any byproduct material permitted by 10 CFR 31.11</p> | <p>E. Prepackaged Kits</p> | <p>E. 5 millicuries total</p> | <p>E. For use in in-vitro studies.</p> |
| <p>F. Yttrium-90 permitted by 10 CFR 35.1000</p> | <p>F. Microspheres (Sirtex Medical Pty Ltd [manufactured by Sirtex Wilmington LLC, Sirtex Germany Manufacturing GmbH, or Sirtex Singapore Manufacturing Pte Ltd], Model SIR-Spheres)</p> | <p>F. 3 curies total</p> | <p>F. For use in permanent manual brachytherapy using Sirtex Medical Model SIR-Spheres Yttrium-90 microspheres and delivery system permitted by 10 CFR 35.1000.</p> |



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-15501-01

Docket or Reference No.:
030-09218

Amendment No. 37

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at: Berkeley Medical Center, 2500 Hospital Drive, Martinsburg, West Virginia, 25401.
11. The Radiation Safety Officer (RSO) for this license is Vivek P. Padha, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. Physicians permitted to work as authorized users for Yttrium-90 SIR-Spheres in accordance with the notification commitments related to documentation of three proctored cases as required in the letter dated June 14, 2024. [ML24169A105]
 - C. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

John L. Blanco, M.D.

Edward Kiggundu, M.D.

Dimitri Misailidis, M.D.

Vivek P. Padha, M.D.

Material and Use

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.500

10 CFR 35.400

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.500

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.500; 10 CFR 35.1000 (limited to the use of Yttrium-90 SIR-Spheres)

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-15501-01

Docket or Reference No.:
030-09218

Amendment No. 37

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated July 20, 2015 [ML15230A407]
- B. Letter dated September 2, 2015 [ML15273A395]
- C. Letter dated March 22, 2022 [ML22081A293]
- D. Letter dated May 26, 2022 [ML22214B602] (limited to Delegation of Authority)
- E. Letter dated February 6, 2024 [ML24045A116]
- F. Letter dated March 8, 2024 [ML24081A250]
- G. Letter dated June 14, 2024 [ML24169A105]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 17, 2024By: _____
Janice Nguyen
Region 1